We are live on !
Find out more
Profund Advisors Portfolio holdings
AUM
$3.48B
Turnover
14.37%
1-Year Est. Return
66.96%
ProFund Advisors manages the ProFunds mutual funds, which include index funds across sectors, bonds, currencies and crypto, as well as leveraged and inverse funds. The ProFunds brand dates from 1997, and its affiliate ProShares began offering leveraged and inverse ETFs in 2006. The Bitcoin ProFund tracks bitcoin futures rather than holding bitcoin itself.
This Fund
S&P 500
This Quarter Est. Return
+3.6%
1 Year Est. Return
+66.96%
3 Year Est. Return
+258.11%
5 Year Est. Return
+342.15%
10 Year Est. Return
+1,333.1%
AUM
$3.48B
AUM Growth
-$153M
(-4.2%)
Cap. Flow
-$155M
Cap. Flow % of AUM
Cap. Flow %
-4.44%
Top 10 Holdings %
Top 10 Hldgs %
41.36%
Holding
1,225
New
50
Increased
319
Reduced
729
Closed
126
Avg Time Held
6.2
years
Top 10 Avg Time Held
4.5
years
Top 20 Avg Time Held
5.7
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
SpaceX
SPCX
|
+$37.8M |
| 2 |
Alumis Inc
ALMS
|
+$2.98M |
| 3 |
Collegium Pharmaceutical
COLL
|
+$1.65M |
| 4 |
Reddit
RDDT
|
+$1.57M |
| 5 |
Septerna Inc
SEPN
|
+$1.45M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$46.8M |
| 2 |
Broadcom
AVGO
|
+$15.2M |
| 3 |
Micron Technology
MU
|
+$13.3M |
| 4 |
Apple
AAPL
|
+$12.8M |
| 5 |
Advanced Micro Devices
AMD
|
+$10.8M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 54.2% |
| 2 | Healthcare | 10.88% |
| 3 | Communication Services | 8.15% |
| 4 | Consumer Discretionary | 7.38% |
| 5 | Industrials | 4.14% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
176
CRISPR Therapeutics
CRSP
$4.97B
| $2.3M | 0.07% |
41,562
+12,479
| +43% | +$673K |
2022 Q1
18 quarters
|
|
177
Roivant Sciences
ROIV
$26.7B
| $2.3M | 0.07% |
62,821
+6,070
| +11% | +$220K |
2023 Q1
14 quarters
|
|
178
Neurocrine Biosciences
NBIX
$14.9B
| $2.29M | 0.07% |
16,173
+5,539
| +52% | +$890K |
2015 Q3
44 quarters
|
|
179
GE Vernova
GEV
$227B
| $2.29M | 0.07% |
2,411
-365
| -13% | -$362K |
2024 Q2
9 quarters
|
|
180
Cytokinetics
CYTK
$8.76B
| $2.29M | 0.07% |
34,681
+9,109
| +36% | +$695K |
2021 Q3
20 quarters
|
|
181
Kinross Gold
KGC
$23.7B
| $2.27M | 0.07% |
94,177
-861
| -0.9% | -$23K |
2015 Q3
44 quarters
|
|
182
RTX Corp
RTX
$270B
| $2.27M | 0.07% |
12,203
-1,709
| -12% | -$350K |
2013 Q2
53 quarters
|
|
183
BioMarin Pharmaceuticals
BMRN
$11.3B
| $2.25M | 0.06% |
37,548
+9,582
| +34% | +$603K |
2013 Q2
53 quarters
|
|
184
Welltower
WELL
$172B
| $2.25M | 0.06% |
9,768
+2,192
| +29% | +$518K |
2013 Q2
53 quarters
|
|
185
Alkermes
ALKS
$7.61B
| $2.25M | 0.06% |
55,421
+15,394
| +38% | +$749K |
2013 Q2
53 quarters
|
|
186
Oneok
OKE
$61.2B
| $2.23M | 0.06% |
26,156
-7,126
| -21% | -$656K |
2013 Q2
53 quarters
|
|
187
GE HealthCare
GEHC
$34.6B
| $2.2M | 0.06% |
33,695
-2,719
| -7% | -$184K |
2023 Q1
14 quarters
|
|
188
Morgan Stanley
MS
$288B
| $2.19M | 0.06% |
11,658
+1,144
| +11% | +$243K |
2013 Q2
53 quarters
|
|
189
JD.com
JD
$34.7B
| $2.19M | 0.06% |
82,245
-5,483
| -6% | -$159K |
2014 Q3
48 quarters
|
|
190
Revolution Medicines
RVMD
$41B
| $2.14M | 0.06% |
10,422
+1,105
| +12% | +$219K |
2023 Q1
14 quarters
|
|
191
Petrobras Class A
PBR.A
$125B
| $2.14M | 0.06% |
112,557
-5,012
| -4% | -$85.5K |
2013 Q2
53 quarters
|
|
192
GRAIL Inc
GRAL
$6.41B
| $2.13M | 0.06% |
15,218
-4,860
| -24% | -$385K |
2024 Q4
7 quarters
|
|
193
Travelers Companies
TRV
$81.2B
| $2.11M | 0.06% |
5,923
+236
| +4% | +$86.4K |
2013 Q2
53 quarters
|
|
194
Citigroup
C
$203B
| $2.11M | 0.06% |
16,298
+1,251
| +8% | +$168K |
2013 Q2
53 quarters
|
|
195
Philip Morris
PM
$325B
| $2.11M | 0.06% |
11,037
-360
| -3% | -$68K |
2013 Q2
53 quarters
|
|
196
Devon Energy
DVN
$57.4B
| $2.1M | 0.06% |
45,643
-15,275
| -25% | -$701K |
2013 Q2
53 quarters
|
|
197
Oruka Therapeutics
ORKA
$6.41B
| $2.05M | 0.06% |
24,649
+2,637
| +12% | +$248K |
2025 Q4
3 quarters
|
|
198
Dell
DELL
$270B
| $2.03M | 0.06% |
3,779
-279
| -7% | -$131K |
2024 Q3
8 quarters
|
|
199
Travere Therapeutics
TVTX
$4.75B
| $2.03M | 0.06% |
34,448
+3,874
| +13% | +$237K |
2023 Q1
14 quarters
|
|
200
Royal Gold
RGLD
$19.4B
| $2.02M | 0.06% |
8,577
+238
| +3% | +$54.6K |
2013 Q2
53 quarters
|
|
Similar funds
TC
Profund Advisors's Q3 2026 Portfolio in Review
As of Q3 2026, Profund Advisors held 1,225 positions worth $3.48B, down 4.2% from $3.64B the previous quarter. Its ten largest holdings account for 41% of the portfolio.
Profund Advisors withdrew a net $155M in Q3 2026, closing 126 positions and reducing 729 holdings. Its most notable exit was Electronic Arts, an estimated $5.2M position sold in full.
By sector, the portfolio is most concentrated in Technology at 54% of assets, down from 56% a quarter earlier, followed by Healthcare and Communication Services.
Against the trend, Profund Advisors opened a new position in SpaceX worth $41.3M.
- Profund Advisors's largest Q3 2026 buy was SpaceX: 273,453 shares worth $41.3M.
- Profund Advisors added most to Alumis Inc in Q3 2026, an estimated $2.98M increase.
- Profund Advisors's biggest Q3 2026 reduction was NVIDIA, cutting an estimated $46.8M.
- Profund Advisors fully exited Electronic Arts in Q3 2026, selling an estimated $5.2M.
- Profund Advisors's ten largest holdings make up 41% of its $3.48B portfolio in Q3 2026.
- Profund Advisors opened 50 new positions and closed 126 in Q3 2026.
- Profund Advisors's portfolio value fell 4.2% quarter-over-quarter to $3.48B.
Based on Profund Advisors's 13F filing for Q3 2026, filed 29 Oct 2026.